Annexon, Inc.

NasdaqGS:ANNX Stock Report

Market Cap: US$553.2m

Annexon Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Doug Love

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage24.2%
CEO tenure10yrs
CEO ownership0.3%
Management average tenure2.5yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Sep 27
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 04

Annexon: Unforced Error Sullies Prospects

Apr 03

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

Nov 10
Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Jul 25
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Apr 11
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Feb 14
Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Dec 28
We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Sep 16

Annexon: A First Take

Aug 21

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Aug 08

Annexon to raise $130M in stock and warrant offering

Jul 08

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Apr 16
We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Jan 01
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Sep 08
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

May 22
We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Feb 06
We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome

Dec 21

Annexon Biosciences EPS misses by $0.43

Nov 16

CEO Compensation Analysis

How has Doug Love's remuneration changed compared to Annexon's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$118m

Jun 30 2024n/an/a

-US$115m

Mar 31 2024n/an/a

-US$121m

Dec 31 2023US$2mUS$593k

-US$134m

Sep 30 2023n/an/a

-US$141m

Jun 30 2023n/an/a

-US$143m

Mar 31 2023n/an/a

-US$145m

Dec 31 2022US$4mUS$569k

-US$142m

Sep 30 2022n/an/a

-US$145m

Jun 30 2022n/an/a

-US$145m

Mar 31 2022n/an/a

-US$140m

Dec 31 2021US$8mUS$534k

-US$130m

Sep 30 2021n/an/a

-US$116m

Jun 30 2021n/an/a

-US$103m

Mar 31 2021n/an/a

-US$84m

Dec 31 2020US$5mUS$446k

-US$70m

Sep 30 2020n/an/a

-US$56m

Jun 30 2020n/an/a

-US$45m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$3mUS$396k

-US$38m

Sep 30 2019n/an/a

-US$34m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$518kUS$379k

-US$18m

Compensation vs Market: Doug's total compensation ($USD2.45M) is about average for companies of similar size in the US market ($USD2.13M).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.

CEO

Doug Love (56 yo)

10yrs

Tenure

US$2,453,184

Compensation

Mr. Douglas Love, Esq., J.D, also known as Doug, has been the President, Director and Chief Executive Officer of Annexon Inc. since December 2014. He has extensive business and legal leadership experience...

Leadership Team

NamePositionTenureCompensationOwnership
Douglas Love
CEO, President & Director10yrsUS$2.45m0.28%
$ 1.5m
Dean Artis
Chief Scientific Officer & Executive VP1.9yrsUS$1.83m0.047%
$ 261.2k
Ted Yednock
Executive VP3.2yrsUS$1.14m0.067%
$ 370.4k
Jennifer Lew
Executive VP5.5yrsUS$1.44m0.026%
$ 142.8k
Michael Overdorf
Executive VP & Chief Business Officer4.4yrsUS$1.40m0.033%
$ 185.2k
Henk-Andre Kroon
Senior Vice President of Translational Medicineno datano datano data
Jamie Dananberg
Executive VP & Chief Medical Officer1.4yrsno datano data
Shikhar Agarwal
Senior VP & Head of Commercialless than a yearno datano data
Sunil Mehta
Senior VP of Medical Affairsless than a yearno datano data

2.5yrs

Average Tenure

59.5yo

Average Age

Experienced Management: ANNX's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Douglas Love
CEO, President & Director10yrsUS$2.45m0.28%
$ 1.5m
Ted Yednock
Executive VP1.1yrsUS$1.14m0.067%
$ 370.4k
Muneer Satter
Independent Director10yrsUS$103.93k0.76%
$ 4.2m
Thomas Wiggans
Independent Chairman7.8yrsUS$132.43k0.00025%
$ 1.4k
Jung Choi
Independent Director4.5yrsUS$100.93k0%
$ 0
William Waddill
Independent Director3.3yrsUS$103.43k0%
$ 0
Thomas Maniatis
Member of Scientific Advisory Boardno datano datano data
David Holtzman
Member of Scientific Advisory Boardno datano datano data
Stephen Hauser
Member of Scientific Advisory Boardno datano datano data
Jeffrey Goldberg
Member of Scientific Advisory Boardno datano datano data
P. Willison
Member of Scientific Advisory Boardno datano datano data
Beth Stevens
Member of Scientific Advisory Boardno datano datano data

6.2yrs

Average Tenure

66yo

Average Age

Experienced Board: ANNX's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 05:30
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Annexon, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Thomas ShraderBTIG
Pete StavropoulosCantor Fitzgerald & Co.